242 related articles for article (PubMed ID: 25761093)
1. Optimized patient-trajectory for patients undergoing treatment with high-dose chemotherapy and autologous stem cell transplantation.
Bartels FR; Smith NS; Gørløv JS; Grufstedt HK; Nexø C; Kehlet H; Sjøgren P; Kjeldsen L; Høgdal N
Acta Oncol; 2015 May; 54(5):750-8. PubMed ID: 25761093
[TBL] [Abstract][Full Text] [Related]
2. Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation.
Dimeo FC; Tilmann MH; Bertz H; Kanz L; Mertelsmann R; Keul J
Cancer; 1997 May; 79(9):1717-22. PubMed ID: 9128987
[TBL] [Abstract][Full Text] [Related]
3. Physical exercise prior to hematopoietic stem cell transplantation: A feasibility study.
van Haren IEPM; Staal JB; Potting CM; Atsma F; Hoogeboom TJ; Blijlevens NMA; Nijhuis-van der Sanden MWG
Physiother Theory Pract; 2018 Oct; 34(10):747-756. PubMed ID: 29336645
[TBL] [Abstract][Full Text] [Related]
4. Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study.
Tuchman SA; Lane A; Hornsby WE; Bishop C; Thomas S; Herndon JE; Long G; Gasparetto C; Jones LW
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):103-9. PubMed ID: 25445473
[TBL] [Abstract][Full Text] [Related]
5. PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma.
McCourt O; Fisher A; Ramdharry G; Roberts AL; Land J; Rabin N; Yong K
BMJ Open; 2020 Jan; 10(1):e033176. PubMed ID: 32001493
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
[TBL] [Abstract][Full Text] [Related]
7. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
8. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
9. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
10. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
12. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
13. Lessons learnt from a process evaluation of an exercise intervention in patients treated with autologous stem cell transplantation.
Persoon S; Chinapaw MJM; Buffart LM; Brug J; Kersten MJ; Nollet F
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 28960542
[TBL] [Abstract][Full Text] [Related]
14. Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT pilot randomised controlled trial.
McCourt O; Fisher A; Ramdharry G; Land J; Roberts AL; Rabin N; Yong K
Acta Oncol; 2023 Jul; 62(7):696-705. PubMed ID: 36794394
[TBL] [Abstract][Full Text] [Related]
15. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and benefits of a structured prehabilitation programme prior to autologous stem cell transplantation (ASCT) in patients with myeloma; a prospective feasibility study.
Mawson S; Keen C; Skilbeck J; Ross H; Smith L; Dixey J; Walters SJ; Simpson R; Greenfield DM; Snowden JA
Physiotherapy; 2021 Dec; 113():88-99. PubMed ID: 34563917
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem-cell transplantation restores the functional properties of CD14+CD16+ monocytes in patients with myeloma and lymphoma.
Dayyani F; Joeinig A; Ziegler-Heitbrock L; Schmidmaier R; Straka C; Emmerich B; Meinhardt G
J Leukoc Biol; 2004 Feb; 75(2):207-13. PubMed ID: 14576364
[TBL] [Abstract][Full Text] [Related]
18. A randomized feasibility study of a 12-week community-based exercise program for people with Huntington's disease.
Busse M; Quinn L; Debono K; Jones K; Collett J; Playle R; Kelly M; Simpson S; Backx K; Wasley D; Dawes H; Rosser A;
J Neurol Phys Ther; 2013 Dec; 37(4):149-58. PubMed ID: 24232362
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Chang WJ; Kang ES; Lee ST; Kim SH; Kim DW; Kim SJ; Kim K
Acta Haematol; 2014; 132(2):226-32. PubMed ID: 24732093
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.
Lemieux E; Hulin C; Caillot D; Tardy S; Dorvaux V; Michel J; Gastinne T; Rossi C; Legouge C; Touzeau C; Planche L; Loirat M; Lafon I; Moreau P
Biol Blood Marrow Transplant; 2013 Mar; 19(3):445-9. PubMed ID: 23186983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
